Mesenchymal Subtype of Triple-Negative Breast Cancer: A Review of Specific Features

被引：0

作者：

Krakhmal, Nadezhda V. ^{[1
,2
]}

Babyshkina, Natalia N. ^{[1
,2
]}

Vtorushin, Sergey V. ^{[1
,2
]}

机构：

[1] Siberian State Med Univ, Dept Pathol, Minist Hlth Russia, Tomsk, Russia

[2] RAS, Canc Res Inst, Tomsk Natl Res Med Ctr,Lab Mol Oncol & Immunol, Dept Gen & Mol Pathol,Dept Expt Oncol, Tomsk, Russia

来源：

INTERNATIONAL JOURNAL OF BIOMEDICINE | 2023年 / 13卷 / 01期

关键词：

triple-negative breast cancer; epithelial-mesenchymal transition; molecular markers;

D O I：

10.21103/Article13(1)_RA2

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Triple-negative breast cancer (TNBC) is characterized by high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Currently, four subtypes in the classification of TNBC are distinguished, which differ from each other in morphological manifestations, molecular genetic features, survival rates, prognosis parameters, and tumor resistance to therapy. A special place in this breast tumors group is occupied by the mesenchymal subtype, the frequency percentage of which varies from 7% to 28%, according to different data. The mesenchymal subtype of TNBC (M-TNBC) is characterized by the expression of molecular markers related to the epithelial-mesenchymal transition (EMT) program and cancer stem cells. M-TNBC has a highly aggressive behavior and worse prognosis due to its invasive and stem-like features, which correlate with metastatic dissemination and resistance to therapies. This review discusses the current knowledge regarding the mesenchymal TNBC subtype and its response to conventional therapeutic strategies. The complex approach to finding effective treatment options to restore immunocompetence in mesenchymal breast cancer patients is the final goal for further extended studies.(International Journal of Biomedicine. 2023;13(1):14-19.)

引用

页码：14 / 19

页数：6

共 17 条

[1] DCLK1 Marks a Morphologically Distinct Subpopulation of Cells With Stem Cell Properties in Preinvasive Pancreatic Cancer [J].

Bailey, Jennifer M. ;

Alsina, Janivette ;

Rasheed, Zeshaan A. ;

McAllister, Florencia M. ;

Fu, Ya-Yuan ;

Plentz, Ruben ;

Zhang, Hao ;

Pasricha, Pankaj J. ;

Bardeesy, Nabeel ;

Matsui, William ;

Maitra, Anirban ;

Leach, Steven D. .

GASTROENTEROLOGY, 2014, 146 (01) :245-256

[2] Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer [J].

Burstein, Matthew D. ;

Tsimelzon, Anna ;

Poage, Graham M. ;

Coyington, Kyle R. ;

Contreras, Alejandro ;

Fuqua, Suzanne A. W. ;

Sayage, Michelle I. ;

Osborne, C. Kent ;

Hilsenbeck, Susan G. ;

Chang, Jenny C. ;

Mills, Gordon B. ;

Lau, Ching C. ;

Brown, Powel H. .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1688-1698

[3] Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells [J].

Chandrakesan, Parthasarathy ;

Yao, Jiannan ;

Qu, Dongfeng ;

May, Randal ;

Weygant, Nathaniel ;

Ge, Yang ;

Ali, Naushad ;

Sureban, Sripathi M. ;

Gude, Modhi ;

Vega, Kenneth ;

Bannerman-Menson, Eddie ;

Xia, Lijun ;

Bronze, Michael ;

An, Guangyu ;

Houchen, Courtney W. .

MOLECULAR CANCER, 2017, 16

[4] Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma [J].

Gonzalez-Martinez, Silvia ;

Perez-Mies, Belen ;

Carretero-Barrio, Irene ;

Luisa Palacios-Berraquero, Maria ;

Perez-Garcia, Jose ;

Cortes, Javier ;

Palacios, Jose .

CANCERS, 2020, 12 (07) :1-13

[5] Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype [J].

Harano, Kenichi ;

Wang, Ying ;

Lim, Bora ;

Seitz, Robert S. ;

Morris, Stephan W. ;

Bailey, Daniel B. ;

Hout, David R. ;

Skelton, Rachel L. ;

Ring, Brian Z. ;

Masuda, Hiroko ;

Rao, Arvind U. K. ;

Van Laere, Steven ;

Bertucci, Francois ;

Woodward, Wendy A. ;

Reuben, James M. ;

Krishnamurthy, Savitri ;

Ueno, Naoto T. .

PLOS ONE, 2018, 13 (10)

[6] Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping [J].

Hartung, Carolin ;

Porsch, Martin ;

Stueckrath, Kathrin ;

Kaufhold, Sandy ;

Staege, Martin S. ;

Hanf, Volker ;

Lantzsch, Tilmann ;

Uleer, Christoph ;

Peschel, Susanne ;

John, Jutta ;

Poehler, Marleen ;

Weigert, Edith ;

Buchmann, Joerg ;

Buerrig, Karl-Friedrich ;

Schueler, Kathleen ;

Bethmann, Daniel ;

Grosse, Ivo ;

Kantelhardt, Eva Johanna ;

Thomssen, Christoph ;

Vetter, Martina .

BREAST CARE, 2021, 16 (06) :637-647

[7] Clinicopathological features of metaplastic breast carcinoma [J].

Hasdemir, Oguz Ahmet ;

Tokgoz, Serhat ;

Koybasioglu, Fulya ;

Karabacak, Harun ;

Yucesoy, Cuneyt ;

Imamoglu, Goksen Inanc .

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 27 (04) :509-513

[8] Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features [J].

Herrera Juarez, Mercedes ;

Tolosa Ortega, Pablo ;

Sanchez de Torre, Ana ;

Ciruelos Gil, Eva .

BREAST CARE, 2020, 15 (03) :208-216

[9] Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers [J].

Kim, Sewha ;

Moon, Byung-In ;

Lim, Woosung ;

Park, Sanghui ;

Cho, Min Sun ;

Sung, Sun Hee .

CLINICAL BREAST CANCER, 2018, 18 (05) :E1123-E1132

[10] Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer [J].

Kumar, Sandeep ;

Bal, Amanjit ;

Das, Ashim ;

Loriya, Ishita ;

Khare, Siddhant ;

Bhattacharya, Shalmoli ;

Singh, Gurpreet .

BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (03) :625-633

← 1 2 →